RenovoDerm Acquisition, Valuation, Funding & Investors

Expedition Therapeutics is a San Diego-headquartered clinical-stage biotech developing oral therapies for inflammatory respiratory diseases. Its lead candidate, EXPD-101, inhibits dipeptidyl peptidase 1 to reduce neutrophilic inflammation in chronic obstructive pulmonary disease and bronchiectasis. The company completed Phase 1 trials in 2023 and plans Phase 2 studies in 2024 across Europe and North America. Expedition in-licenses assets while building internal pipelines, supported by a team from GSK and AstraZeneca. It operates R&D facilities in La Jolla, California.

Galvanize Therapeutics is a Boston-headquartered medical device company developing pulsed field ablation platforms for respiratory, cardiac, and oncology applications. Its portfolio features the Galaxy system for bronchoscopic lung volume reduction in chronic obstructive pulmonary disease patients and the Pulse Field Ablation platform for atrial fibrillation. The company targets solid tumors through non-thermal tissue ablation and holds FDA Breakthrough Device Designation for its cardiac rhythm management tools. Backed by Apple Tree Partners since its 2022 inception, Galvanize Therapeutics advances therapies across U.S. clinical sites and international partnerships.

SetPoint Medical is a Los Angeles-based medical device company developing the SetPoint System, an implantable vagus nerve stimulator for treating rheumatoid arthritis in adults unresponsive to conventional therapies. The wireless device modulates inflammation via bioelectronic signals. SetPoint Medical advances clinical trials in the United States and Europe for autoimmune indications.

Direct Biologics is an Austin-based developer and cGMP manufacturer of regenerative biologics derived from human amniotic tissue and umbilical cord sources. The company produces products like EmD (extracellular microenvironment dressing) for wound care and DBM (decellularized bone matrix) for orthopedic applications. As a leader in the biologics space, Direct Biologics supplies hospitals, surgery centers, and clinics with shelf-stable allografts that promote tissue repair and reduce inflammation. Operating FDA-registered facilities, the firm adheres to stringent quality standards for clinical use in sports medicine, spine surgery, and general orthopedics across the United States.

Sunmax Biotechnology Co Ltd is a biomedical company in Taiwan. It is engaged in the development, manufacturing, and commercialization of Sunmax medical devices and bio-surgical products. Additionally, it also researches, develops, manufactures and sales biomedical material grade collagen and related products. The company's products include medical products, biomedical materials, and porcine collagen skin care products.

Ultragreen Ai Ltd is engaged in the sales of Indocyanine Green (ICG) pharmaceutical products and cardiology Picture Archiving and Communication System (PACS) software and associated products and services. It provides a fluorescence imaging ecosystem designed to support surgeons with real-time perfusion data and visualization capabilities. The company is organised into business units based on its products and services and operates in (a) the Diagnostic Green (DxG) - Americas segment; (b) the DxG - Rest of the World segment; and (c) the UltraLinQ segment. The company generates the maximum of its revenue from the the DxG - Rest of the World segment, which focuses on the sales of ICG vials and related pharmaceutical products.

MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.

Delfi Diagnostics is a Baltimore-headquartered developer of blood-based cancer screening tests using AI and genome sequencing. Its Delfi test analyzes DNA fragmentation patterns to detect lung cancer at 89 percent sensitivity in stage I cases. Clinical trials with Johns Hopkins involve over 1,000 patients, targeting multi-cancer early detection. Founded in 2019 by genome experts, the company secured FDA breakthrough designation in 2023.

Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.

Embark is a Boston-based canine genetics company offering DNA testing kits. The platform analyzes over 200,000 genetic markers using CLIA-certified SNP chips to screen for breed, health risks, traits, and preventive care recommendations, contributing to veterinary research on nutrition and diseases.

Hyperice is a Carlsbad, California-headquartered company manufacturing percussion massage devices, compression boots, and thermal wearables for athletic recovery. Its Hypervolt line delivers targeted vibration therapy up to 3,200 percussions per minute, adopted by over 400 professional sports teams including NBA's Los Angeles Lakers and NFL's New England Patriots. Founded in 2012, Hyperice expands into consumer fitness with Normatec recovery systems used in Olympic training facilities worldwide.

Ring Therapeutics is a biotechnology company developing Anellovector gene therapies derived from human commensal viruses for redosable and targeted treatments. Backed by Flagship Pioneering and based in Cambridge, Massachusetts, it advances platforms beyond traditional gene replacement for diseases like liver disorders and muscle wasting. Founded in 2022, Ring Therapeutics pioneers viral vectors for immunology and oncology applications.

SiBionics is a Chinese medical device company developing AI-based devices for chronic disease management, including its GS1 and GS3 continuous glucose monitoring (CGM) systems for people with diabetes. Its GS3 sensor is described as the world's thinnest CGM and has earned CE Mark approval alongside other products in its lineup, placing the company in the competitive global CGM market alongside established international players.

Medrobotics is a medical robotics firm commercializing the Flex Robotic System, a steerable and shapeable endoscopic platform. The system enables minimally invasive access to complex anatomies like the throat, lung, and prostate through a single small incision, surpassing rigid tool limitations.

SmartCella is a Milan-based biotechnology company advancing cell therapy delivery for cardiac regeneration. Its SmartCella device enables precise intracoronary injection of stem cells, drugs, and RNA therapeutics during procedures. Tested in preclinical models for heart failure and myocardial infarction, it partners with clinics in Italy and the EU. Founded in 2016, SmartCella focuses on interventional cardiology applications.

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Strand Therapeutics is a Cambridge-headquartered biotechnology firm founded in 2017 that engineers programmable mRNA medicines using synthetic biology principles. The platform deploys logic circuits within cells to detect tumor-specific signals and produce cancer-fighting proteins on demand, such as cytokines for immunotherapy. Their lead candidates target solid tumors including glioblastoma and head-and-neck cancers through intravenous administration. Strand Therapeutics collaborates with academic institutions like MIT and has progressed multiple programs into preclinical testing for oncology applications.